APOE and metabolic syndrome: Recent studies have demonstrated that ponatinib could improve dyslipidemia and atherosclerotic plaque formation in apolipoprotein E-deficient mice, suggesting that ponatinib exerted a significant role in lipid metabolism (Pouwer et al., 2018).